Promoted Content Promoted Content


Find Clinical Drug Development Pipelines & Deals | PipelineProspector


All Data

Filters Filter refresh
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): OATD-01

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: OATD-01

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Galapagos

            Deal Size: $380.8 million Upfront Cash: $29.7 million

            Deal Type: Licensing Agreement November 05, 2020


            OncoArendi Therapeutics gains global development and commercialization rights of OncoArendi’s OATD-01. OATD-01 is a Phase 2-ready chitotriosidase/acidic mammalian chitinase inhibitor to treat Idiopathic pulmonary fibrosis and other diseases with a fibrotic component.